Skip to main content

CCTG Connection


Published:
Category: Office of the Director
Dr Janet Dancey CCTG year in review: 2025 accomplishments and 2026 strategic priorities
2025 was marked by scientific excellence, operational achievement, and renewed national and international recognition of the Canadian Cancer Trials Group’s leadership in academically driven cancer clinical trials. Read More
Published:
Category: Trials
Trial closure: IC.8

Please note that IC.8: COV-IMMUNO - A Randomized, Phase III Trial of Immunization with IMM-101 versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure trial has permanently closed.

For additional information please visit the IC8 CCTG trial page.

Read More
Published:
Category: Trials
Trial closure: ICC.1

The ICC.1: NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study trial has permanently closed.

Read More


Published:
Category: Group updates
The CCTG 2026 Annual Spring Meeting of Participants

CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.

Read More
Published:
Category: Group updates
Tissue Bank Holiday Season Shipment Notice and Central Office closure

CCTG Central Office 2025/2026 Holiday hours and closures 

  • December 24 – limited coverage 9am - 12pm EST
  • December 25 and 26 – office is closed
  • December 29 and 30 - limited coverage  9am – 5pm EST
  • December 31 - limited coverage  9am – 12pm EST
  • January 1st - office is closed  
  • January 2nd - limited coverage 9am – 5pm EST

Normal office hours resume on January 5th, 2026 at 8:30 am EST

Shipment of Specimens for Banking + Kit Supply

Read More
Published:
Category: Publications
Publication: Post Hoc Analysis CRC6
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. This post hoc analysis used a clinically validated, tumor-informed assay to determine ctDNA status in 940 patients with stage III colon cancer and found that ctDNA negativity was highly associated with improved survival.
Read More
Published:
Category: Publications
Publication: Correlative CO.28
A new correlative study from CO.28 has been published: Detection of Molecular Residual Disease by Circulating Tumor DNA in Early-Stage Node-Negative Rectal Cancers (CCTG CO.28) Using a Tumor-Informed Assay
Read More
Published:
Category: Publications
Poster Presentation at the Society for Neuro-Oncology Annual Meeting
Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study
 
A CCTG poster presentation at the Society for Neuro-Oncology Annual Meeting, held November 19-23, 2025 in Honolulu. The abstract was then published in the journal Neuro-Oncology.
 
Patients with progressive IDH-mutant grade 2-3 glioma have limited therapeutic options.
Read More